Autolus Therapeutics plc announced that Dr. Veronica Hersberger was appointed as Senior Vice President, Medical Affairs in Second Quarter 2023 and has started to build up this critical function as the Company prepares obe-cel for launch. Veronica joined Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer. Prior to that, Veronica was Global Product Leader for the cancer therapies Calquence and Lumoxiti at AstraZeneca and led Medical Affairs for the Hematology Franchise at Roche where she was also involved in the development of a range of oncology programs. Additionally, Miranda Neville has been promoted to Senior Vice President, Project Management, effective immediately.

Miranda leads the obe-cel program and has served in various roles at Autolus, most recently as Vice President, Head of Program and Portfolio Management. Miranda has over 20 years of experience in project management, engineering, capital projects and operations. Prior to leading the obe-cel program, Miranda ran Autolus?

commercial manufacturing capital project delivering the Nucleus facility in record time. Prior to Autolus, Miranda supported several consulting projects across large biopharmaceutical companies as well as clinical stage gene therapy programs. At Human Genome Sciences Inc., Miranda led program management for the Benlysta program in systemic lupus erythematosus (SLE) through a successful BLA process, resulting in regulatory approval. Dr. Veronica Hersberger was appointed as Senior Vice President, Medical Affairs in Second Quarter 2023 and has started to build up this critical function as the Company prepares obe-cel for launch.

Veronica joins Autolus from TargImmune Therapeutics AG, where she was Chief Medical Officer. Prior to that she was at AstraZeneca, as Global Product Leader for the cancer therapies Calquence and Lumoxiti. She also had a long career at F. Hoffmann-La Roche AG where she was Medical Affairs Franchise Head Hematology and was involved in the development and delivery of a number of significant cancer therapies, including Herceptin SC, Kadcyla and Perjeta across the full range of clinical development from early stage through to commercialization.

She was responsible for the first in human Perjeta studies and was involved in the regulatory interactions for filing Herceptin in adjuvant breast cancer, gastric cancer, and 1-weekly dosing and for Kadcyla in metastatic breast cancer. She has broad experience across many aspects of oncology including most solid tumors and various hematological malignancies, plus experience in non-malignant diseases such as hemophilia. Dr. Hersberger holds a medical degree from the University of Buenos Aires.

She is a board-certified dermatologist and brings more than 20 years of industry experience in oncology and hematology. Ms. Neville joined Autolus in 2018 from the consulting firm AllianceBio where she spent 4 years as a Partner and supported several clinical stage CDMO and commercial biopharmaceutical companies. Following her BS at West Virginia University, she started her career at Human Genome Sciences Inc. She spent 10 years at HGS in a variety of roles including Manufacturing, Engineering & Program Management, prior to its acquisition by GlaxoSmithKline.